| Patient | Ernest Shackleton |
|---|---|
| Date of birth | 1874-02-15 |
| Identifiers | MRN HR-EX001-SYN-TD; SSN (made up) 000-01-7763 |
| Document date | 1921-09-08 |
| Author | Cormac Ellingsworth-Daly, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Pre-departure review: exercise test and expedition medical plan. [S]
Mr. Shackleton returns nine days before his expedition sails, after a symptom-limited exercise test this morning. He has had no chest pain since the stent, has completed 18 sessions of cardiac rehabilitation, and walks briskly every day. The back strain from two weeks ago has settled with heat and acetaminophen, and he has delegated the lifting. He has not smoked for sixteen weeks and takes varenicline. He drinks two drinks at most, on four evenings a week. He takes aspirin, clopidogrel, atorvastatin, ezetimibe, and metoprolol daily. He wants to know what to carry and what to do if his heart gives trouble at sea. [S]
| Element | Detail |
|---|---|
| Angina | None |
| Rehabilitation | 18 sessions completed |
| Back | Strain settled |
| Tobacco | Not smoked for sixteen weeks |
| Alcohol | Two drinks at most on four evenings a week |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, fainting, or swelling |
| Respiratory | Negative | No cough or breathlessness |
| Hematologic | Negative | No bleeding beyond occasional bruises |
| Musculoskeletal | Negative | Back pain gone; no muscle aches |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-12 | active | S |
| Atorvastatin 80 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-12 | active | S |
| Metoprolol succinate extended-release 50 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-12 to 1921-05-26 | stopped | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 doses | as needed for chest pain, up to 3 doses | Sublingual route | 1921-05-12 | active | S |
| Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titration | twice a day after titration | Oral route | 1921-05-12 | active | S |
| Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-05-26 | active | S |
| Clopidogrel 75 mg tablet, one tablet by mouth daily for six months after the stent (600 mg loading dose before the procedure) | once daily for six months | Oral route | 1921-07-01 | active | S |
| Ezetimibe 10 mg tablet, one tablet by mouth daily | once daily | Oral route | 1921-07-21 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1921-09-08 | Body height | 175 | cm | S |
| 1921-09-08 | Body weight | 83 | kg | S |
| 1921-09-08 | Body mass index (BMI) [Ratio] | 27.1 | kg/m2 | S |
| 1921-09-08 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1921-09-08 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1921-09-08 | Heart rate | 58 | /min | S |
| 1921-09-08 | Respiratory rate | 14 | /min | S |
| 1921-09-08 | Body temperature | 36.6 | Cel | S |
| 1921-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1921-09-08 | Cholesterol [Mass/volume] in Serum or Plasma | 108 | mg/dL | <=199 mg/dL | Normal | S |
| 1921-09-08 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 45 | mg/dL | >=40 mg/dL | Normal | S |
| 1921-09-08 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 44 | mg/dL | Below 100 for the general population; below 55 is his treatment target | Normal | S |
| 1921-09-08 | Triglyceride [Mass/volume] in Serum or Plasma | 95 | mg/dL | <=149 mg/dL | Normal | S |
| 1921-09-08 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.7 | % | <=5.6% | High | S |
| 1921-09-08 | Total score [AUDIT-C] | 3 | {score} | S |
Vital signs recorded on 1921-09-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 120/76, pulse 58, weight 83.0 kg, BMI 27.1 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear to auscultation bilaterally |
| Back | Full, painless movement |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chest tightness and breathlessness on exertion for about three months, brought on by stairs, carrying loads, and walking fast in cold wind and relieved within minutes by rest, never at rest; resting ECG normal; cause not yet established at intake; coronary CT angiography and cardiology consultation requested | resolved | confirmed | R07.89 | S — Synthetic presenting problem anchored to his documented exertional breathlessness; superseded by the diagnosis at the cardiology consultation. |
| Nicotine dependence, cigarettes: about 25 a day since 16 (about 39 pack-years) | active | confirmed | F17.210 | S — Synthetic modern coding anchored to his documented heavy smoking. |
| Chronic coronary disease with stable exertional angina: 80% stenosis of the proximal left anterior descending artery with CT-FFR 0.70, mild right coronary artery disease, coronary calcium score 210, and normal left ventricular function; synthetic modern episode linked to his documented exertional illnesses and the coronary atheroma recorded at his death | active | confirmed | I25.118 | S — Synthetic modern diagnosis made at the cardiology consultation; Macklin's coronary diagnosis is recorded in CLM-0009 and the alternative theories as R. |
| Hyperlipidemia: LDL cholesterol 168 mg/dL and HDL 38 mg/dL at intake | active | confirmed | E78.5 | S — Synthetic modern risk factor; no historical measurement exists. |
| Prediabetes: HbA1c 5.9% at intake | active | confirmed | R73.03 | S — Synthetic modern risk factor; no historical measurement exists. |
| Drug-eluting stent in the proximal left anterior descending artery, placed for angina that persisted on medical therapy; dual antiplatelet therapy for six months | active | confirmed | Z95.5 | S — Synthetic status after the modern procedure. |
| Acute low back strain after lifting crates of stores, without sciatica or red flags; managed without NSAIDs because he takes aspirin and clopidogrel; resolved | resolved | confirmed | S39.012A | S — Synthetic acute problem; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 120/76 mmHg, at target |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 83.0 kg, BMI 27.1, down 3 kg; active daily |
| Examination | Angina frequency and Canadian Cardiovascular Society class, nitroglycerin use | Every visit | Completed today | No angina since the stent |
| Imaging | Symptom-limited exercise ECG before remote, strenuous travel | Once before departure, as agreed at the consultation | Completed today | 11 minutes (about 12.8 METs); no angina or ischemic changes |
| Imaging | Stress imaging, coronary CT angiography, echocardiography, or invasive angiography | Only for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillance | Not indicated | Asymptomatic; no surveillance imaging |
| Medication safety | Dual antiplatelet therapy: adherence and bleeding | Every visit during dual therapy | Completed today | Both taken daily; no bleeding; stop date for clopidogrel written on the summary |
| Medication safety | Adherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for angina | Every visit | Completed today | All taken daily; supply for the voyage arranged |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months | Completed today | LDL 44 mg/dL on atorvastatin and ezetimibe; at target; next on his return |
| Laboratory | HbA1c for prediabetes | Every 3 to 6 months while lifestyle change is under way, then yearly | Completed today | 5.7%, from 5.9% |
| Self-management | Tobacco use and cessation support (varenicline with counseling) | Every visit | Completed today | Abstinent for sixteen weeks |
| Survey | Alcohol use (AUDIT-C) and brief intervention | Each visit until within limits | Completed today | AUDIT-C 3 |
| Referral | Cardiac rehabilitation referral | Up to 36 sessions | Completed today | 18 sessions completed; home exercise plan for the voyage |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Periodically | Up to date | PHQ-2 0 at the preventive visit |
| Self-management | Influenza and COVID-19 vaccination review | Yearly | Completed today | Influenza vaccine given today; COVID-19 vaccine declined at the preventive visit |
| Self-management | Remote expedition plan (exercise test, medicines, defibrillator, evacuation, cold stress) | Before departure | Completed today | Summary, medicines, defibrillator, satellite link, evacuation plan, and cold-stress advice in place |
Goal progress:
Immunizations given today: Influenza vaccine, 1921-1922 season [S]
Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023); 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Prediabetes and Type 2 Diabetes: Screening (2021)
Follow-up: Review on his return, with lipids and HbA1c. Satellite messages to the clinic and the cardiology team as needed during the expedition. [S]